MVP Act

HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH

Client expense: $490,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2666/S. 4204 - MVP Act, all provisions. H.R. 10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025, issues related to PRV and the Accelerating Kids Access to Care Act. Issues related to the CMMI demonstration on Gene and Cell Therapy.

Client expense: $250,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of gene therapies for rare diseases S. 4204/ H.R. 2666 MVP ACT

Client expense: Not reported · Firm income: $60,000

Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Issues related to 1115 Waivers in Medicaid Preserving and expanding access to Medicaid Providing Realistic Opportunity to Equal and Comparable Treatment (PROTECT) for Rare Act (H.R. 6094) The Menstrual Equity for All Act (H.R. 3646) Medicaid VBPs for Patients (MVP) Act (H.R. 2666/S.4204) Accelerating Kids Access to Care Act (S. 2372)

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to managed care pharmacists; H.R. 1458/S.723 - Access to Prescription Digital Therapeutics Act of 2023; H.R. 2666/S. 4204 - the Medicaid VBPs for Patients (MVP).

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2666/S 4204 - Medicaid Value-Based Payments for Patients (MVP) Act HR 4758/S 2372 - Accelerating Kids' Access to Care Act

Client expense: $130,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Access for inpatient gene therapies Monitor newborn screening issues. Pediatric Review Reauthorization. H.R.2666/S.4204 - MVP Act. H.R.4758/S.2372 - Accelerating Kids Access to Care Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the implementation of H.R.5547/S.476 - Maintaining Investments in New Innovation Act and H.R.7384 - Creating Hope Reauthorization Act of 2024. Pediatric Review Reauthorization. H.R.5539/S.3131 - ORPHAN Cures Act. H.R.2666/S.4204 - MVP Act. H.R.4758/S.2372 - Accelerating Kids Access to Care Act.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).

Client expense: $150,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH

Client expense: $240,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2666 - Medicaid Value-Based Payments for Patients (MVP) Act S 4204 - Medicaid Value-Based Payments for Patients (MVP) Act HR 4758 - Accelerating Kids' Access to Care Act Medicaid Program: Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program (CMS-2434-P)

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

H.R. 2666/S. 4204 - MVP Act, all provisions. Issues related to the CMMI demonstration on Gene and Cell Therapy.

Client expense: $180,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2666/S. 4204, the Medicaid VBPs for Patients (MVP) Act; Center for Medicare and Medicaid Innovations (CMMI) Cell and Gene Therapy Access Model; H.R. 4758/S. 2372, Accelerating Kids Access to Care Act; H.R. 7384, Creating Hope Reauthorization Act of 2024

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of gene therapies for rare diseases S. 4204/ H.R. 2666 MVP ACT

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to managed care pharmacists; S.723/H.R.1458 - Access to Prescription Digital Therapeutics Act of 2023; H.R.2666/S.4204 - the Medicaid VBPs for Patients (MVP).

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDERS

Client expense: $180,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to value based arrangements and reimbursement for regenerative medicine products; H.R. 2666/S. 4204, the Medicaid VBPs for Patients (MVP) Act; Center for Medicare and Medicaid Innovations (CMMI) Cell and Gene Therapy Access Model; H.R. 4758/S. 2372, Accelerating Kids Access to Care Act; H.R. 7384, Creating Hope Reauthorization Act of 2024

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2666/S. 4204 - MVP Act, all provisions. Issues related to the CMMI demonstration on Gene and Cell Therapy.

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of gene therapies for rare diseases S. 4204/ H.R. 2666 MVP ACT

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 4204 and HR 1976, Medicare for All, private equity in health care, Oversight of private equity in health care, Healthcare Ownership Transparency Act.

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE